ARIAD Pharmaceuticals Inc Company News
Old Arcived News About ARIAD Pharmaceuticals Inc
- 7:36 am Ariad Pharm initiates a Phase 3 trial of Iclusigin in chronic phase, second-line patients with chronic myeloid leukemia.
- Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers.
- ARIAD.
- ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries. [Business Wire] - CAMBRIDGE, Mass. & TOKYO--(BUSINESSWIRE)-- ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ: ARIA) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they have entered into an agreement for Otsuka ...
- ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries. [Business Wire] - ARIAD Pharmaceuticals, Inc. and Angelini Pharma, through the Austrian subsidiary CSC Pharmaceuticals, today announced that ARIAD has granted Angelini exclusive rights to commercialize Iclusig® for the indications approved by the European Medicine Agency in Central and Eastern Europe.
- ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia. [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced safety and efficacy follow-up data on Iclusig® , its approved BCR-ABL inhibitor, in patients with a baseline T
- ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting. [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced the schedule of several data presentations on Iclusig® that will take place at the 57th Annual Meeting of the American Society of Hematology being held in Orlando, December 5 to 8, 2015.
- ARIAD Announces Initiation of OPTIC-2L Randomized Phase 3 Trial of ponatinib vs. nilotinib in Second-Line Patients with Chronic-Phase Chronic Myeloid Leukemia. [at noodls] - CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Dec. 7, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a randomized Phase 3 trial of Iclusig® (ponatinib) ...
- ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial. [at noodls] - SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 8, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its ...
- ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial. [at noodls] - ~ Median Follow-up in Trial Now Four Years CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 9, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the ...
- Ariad nabs $77.5 million in licensing pact.
- ARIAD Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today.
- ARIAD Pharmaceuticals (ARIA) Stock Gets ‘Underweight’ Rating at Barclays.
- ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today.
- ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report.
- ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events.
- ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits.
- ARIAD PHARMACEUTICALS INC Financials.
- Ariad reports 3Q loss.
- Ariad Said to Name Panayiotopoulos CEO After Activist Push.
- ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference. [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 22, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference being held in San ...
- ARIAD's Q3 Loss Wider than Expected; Iclusig Sales Fall.
- Do Investors Like Lexicon Pharmaceuticals, Inc..
- Edited Transcript of ARIA earnings conference call or presentation 3-Nov-15 1:30pm GMT.
- Emergent Biosolutions Inc.
- Equities Driven by Market Influences - Research on Opko Health, Ariad Pharmaceuticals, Denbury Resources and Pure Storage. [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 9, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Opko Health ...
- Hedge Funds Are Dumping Ariad Pharmaceuticals, Inc..
- Here's Why Ariad Pharmaceuticals Galloped Higher by 17% in October.
- IBB Falls as Energy Sector Negatively Influences the Market.
- Insider Trading Alert - AEP, JBSS And ARIA Traded By Insiders.
- Insider Trading Alert - SABR, DLTR And ARIA Traded By Insiders.
- Perilous Reversal Watch: ARIAD Pharmaceuticals (ARIA).
- Trades look for rebound in Ariad.
- UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak.
- US stocks rise on IMF outlook, Apple deal.
- Will Ariad Pharmaceuticals.
- [video]Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers.
ARIAD Pharmaceuticals Inc Short Company Overview:
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. The Company's approach to structure-based drug design has led to several molecularly targeted medicines for drug-resistant or difficult-to-treat cancers.